TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04009278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self compression arm
Description: The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
Study: NCT00567658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole or Nexium 40 mg BID is given for four months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole or Nexium 40 mg BID is given for four months.
Study: NCT04657198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine (GSK3844766A)
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine (GSK3844766A)
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine (GSK3844766A)
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
Study: NCT01586923

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: RBC transfusion of different storage age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: RBC transfusion of different storage age
Study: NCT04105218

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
Study: NCT00362986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunscreen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01109953

Intervention type: OTHER
Intervention: Breath-Hold PET/CT image set
Description: In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
Study: NCT05893251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural exercises
Description: The treatment plan includes active postural exercises for the cervical spine.
Study: NCT03303456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application - Ginger.io
Description: the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application - Ginger.io
Description: the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application - Ginger.io
Description: the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
Study: NCT03518762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI)
Description: SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
Study: NCT03046667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley β-glucan
Description: The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
Study: NCT03981484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: single dose of 25 IU/kg of 4-PCC at time of enrollment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood, Plasma, Packed Red Blood Cells
Description: site's standard resuscitation protocol
Study: NCT02256215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT01826227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro-2-deoxy-D-lucose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Study: NCT02204995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy with LRTI
Description: Trapeziectomy with Ligament Reconstruction and Tendon Interposition

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy
Description: Trapeziectomy
Study: NCT00765843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthoses
Description: orthoses are provided for use in standardized shoes that all subjects receive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthoses
Description: orthoses are provided for use in standardized shoes that all subjects receive

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: orthoses
Description: orthoses are provided for use in standardized shoes that all subjects receive
Study: NCT03894852

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR and cytogenetics
Description: detection of SRSF2 gene mutation and cytogenetic studies

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR and cytogenetics
Description: detection of SRSF2 gene mutation and cytogenetic studies
Study: NCT05736081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant
Description: Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
Study: NCT01038557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBC units
Description: When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC units
Description: When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC units
Description: When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
Study: NCT01741857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord derived MSC transplantation for SLE
Study: NCT03244956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg daily for a maximum of 6 weeks of treatment
Study: NCT05198024

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition knowledge
Description: Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge
Description: Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
Study: NCT03244956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg daily for a maximum of 6 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150mg twice daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I
Description: 5.5 GBq

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I
Description: 5.5 GBq
Study: NCT03221634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: IV infusion
Study: NCT03244956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: 0.9mg on two consecutive days after 35 days of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: 0.9mg on two consecutive days after 35 days of treatment
Study: NCT04676191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepiz One+
Description: Simultaneous sleep study with polysomnography and Sleepiz One+

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Simultaneous sleep study with polysomnography and Sleepiz One+
Study: NCT01923246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single WEB intervention
Description: Brief WEB intervention recieved once

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated WEB intervention
Description: WEB intervention recieved twice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single IVR intervention
Description: IVR intervention recieved once

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated IVR intervention
Description: IVR intervention recieved twice
Study: NCT01720186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT 4D imaging in a synchronized mode centered on the thorax.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT 4D imaging in a synchronized mode centered on the thorax.
Study: NCT00225199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visanne (BAY86-5258, SH T00660AA)
Description: orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once daily
Study: NCT02001779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary SEMS loaded with 125I seeds
Description: A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional biliary SEMS
Description: A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
Study: NCT00760383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
Study: NCT00947427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab (anti IL-1beta)
Description: canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injections
Study: NCT02957279

Intervention type: DRUG
Intervention: Antibiotics
Description: In the sepsis group, antibiotics were used when needed.
Study: NCT00704223

Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
Study: NCT04966897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GlycosBio Nutritional Supplement + PERT placebo
Description: The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutritional Supplement + PERT
Description: A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
Study: NCT01297647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urodynamic examination
Description: Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux.
Study: NCT00772577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren Hydrochlorothiazide
Description: Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
Study: NCT00831727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
Study: NCT02477761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient preload
Description: Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
Study: NCT02318927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
Study: NCT05074589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome、5-Fluorouracil、Leucovorin
Description: Irinotecan liposome、5-Fluorouracil、Leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo、5-Fluorouracil、Leucovorin
Description: Placebo、5-Fluorouracil、Leucovorin
Study: NCT01998321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient specific instrument
Description: A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation \& PSI designing and PSI production

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional technique for TKA
Study: NCT02153047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
Study: NCT01261481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 15 mg administered once orally as an intact tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 15 mg administered once via nasogastric tube.
Study: NCT03341286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TK3
Description: Tryptophan and thiamine as on oral supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK3
Description: Tryptophan and thiamine as on oral supplement
Study: NCT04206189

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate group - carbohydrate (400ml)
Description: Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
Study: NCT01030861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teplizumab
Description: intravenous infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo for Teplizumab
Study: NCT01384695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: fluorescent contrast agent, Fluorescein 5ml
Study: NCT03458884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory interval training
Description: A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
Study: NCT01384695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine hemisulfate
Description: 3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
Study: NCT05717881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed.